TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Biocon Ltd.

BIOCON on NSE · 19 Nov 2026

NIFTY 500 F&O

363.65 ▲ +0.47 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Guidance tracker

What BIOCON guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
11 Nov 2026Biocon filed the transcript of its Q2 FY27 earnings call held on November 4, 2026, with the transcript also posted on its website. Management (Chairperson Kiran Mazumdar Shaw and CEO Shreehas Tambe) said the company is moving from investment-led capability building to commercial acceleration and expects H2 FY27 to... NSE copy No results filed since
11 Aug 2026Biocon filed the transcript of its Q1 FY27 earnings call held on August 06, 2026, along with a cover letter to BSE and NSE. On the call, management said group operating revenue grew 10% year-on-year, with biopharmaceuticals up 17% and services revenue down 16%. Management reported group EBITDA of INR902 crores (21%... NSE copy -51.1 %+2.2 %+5.1 %
06 Aug 2026Biocon filed the presentation for its Q1 FY27 earnings call held on August 06, 2026. Q1 FY27 revenue from operations was ₹4,336 Cr, up 10% YoY and down 4% QoQ; EBITDA was ₹902 Cr (21% margin) versus ₹846 Cr a year earlier. Q1 FY27 net profit before exceptional items was ₹145 Cr versus ₹42 Cr in Q1 FY26; reported... NSE copy -51.1 %+2.2 %+5.1 %
01 Jun 2026Biocon Limited filed an investor presentation dated June 2026 under Regulation 30 of the SEBI LODR Regulations, for analyst and institutional investor meetings scheduled on June 02, 2026 and June 08, 2026. Company profile per the presentation: over 47 years of legacy, presence in 120+ countries, 11 manufacturing... NSE copy +349.4 %+10.0 %+2.7 %
14 May 2026Biocon filed the transcript of its Q4 FY26 earnings call held on May 08, 2026, with the BSE and NSE, also posted on its website. Management said Q4 FY26 operating revenue grew 10% year-on-year excluding the one-time generic lenalidomide bonus in Q4 FY25; EBITDA was INR1,073 crores with a 23% margin, up 29%... NSE copy +349.4 %+10.0 %+2.7 %
07 May 2026Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of face value Rs. 5) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board... NSE copy +349.4 %+10.0 %+2.7 %
09 Dec 2025Biocon Limited filed an investor presentation (December 2025) under Regulation 30 ahead of analyst/institutional investor meetings scheduled for December 10 and 11, 2025. The presentation covers a proposed consolidation of Biocon Limited and Biocon Biologics, combining biosimilars, insulins, peptides and complex... NSE copy +472.9 %+9.2 %+0.8 %
18 Nov 2025Biocon filed the transcript of its Q2 FY26 earnings call held on November 12, 2025, with the cover letter dated November 18, 2025. Management said operating revenue was INR 4,296 crores, up 20% year-on-year, with core EBITDA of INR 1,218 crores (28% margin) and reported EBITDA of INR 928 crores (21% margin).... NSE copy +472.9 %+9.2 %+0.8 %
12 Nov 2025Biocon filed the presentation for its Q2 FY26 earnings call held on November 12, 2025. Q2 FY26 revenue from operations was ₹4,296 crore, up 20% YoY and 9% QoQ; total revenue was ₹4,389 crore; EBITDA was ₹928 crore (21% margin); net profit before exceptional items was ₹92 crore versus a loss of ₹13 crore in Q2 FY25.... NSE copy +472.9 %+9.2 %+0.8 %
14 Aug 2025Biocon filed the transcript of its Q1 FY26 earnings call held on August 08, 2025, on the BSE and NSE. Kiran Mazumdar Shaw (management) said operating revenue was INR 3,942 crores, up 15% year-on-year on a like-for-like basis, with core EBITDA of INR 1,003 crores (25% margin). Management said biosimilars revenue... NSE copy -+19.6 %+5.4 %
15 May 2025Biocon filed the transcript of its Q4 FY25 earnings call held on May 9, 2025, with the transcript also posted on its website. Q4 FY25 revenue from operations was INR 4,417 crores, up 15% year-on-year on a like-for-like basis and 16% sequentially; core EBITDA was INR 1,363 crores (31% core operating margin). For... NSE copy -95.2 %+14.8 %-5.7 %
04 Apr 2025Biocon Limited filed a Regulation 30 disclosure with BSE and NSE dated April 04, 2025. The Board of Directors, at its meeting held on April 04, 2025, approved issuance of Commercial Paper up to an amount not exceeding Rs. 600 Crores in one or more tranches on private placement basis. The Board meeting commenced at... NSE copy +154.2 %+12.8 %-1.4 %
07 Feb 2025Biocon filed the transcript of its Q3 FY25 earnings call held on January 31, 2025, with the filing dated February 7, 2025. Management said Q3 FY25 revenue from operations was INR 3,821 crore, up 10% year-on-year on a like-for-like basis; reported net profit was INR 25 crore, and group core EBITDA was INR 1,007... NSE copy +154.2 %+12.8 %-1.4 %
31 Jan 2025Biocon filed the presentation for its Q3 FY25 earnings call, held on January 31, 2025. Per the presentation, Group Operating Revenue grew 10% YoY on a like-for-like basis; Q3 FY25 Revenue from Operations was ₹3,821 Cr versus ₹3,954 Cr in Q3 FY24 and ₹3,590 Cr in Q2 FY25. Q3 FY25 Net Profit (Reported) was ₹25 Cr... NSE copy +154.2 %+12.8 %-1.4 %

Filings tagged as guidance, newest first (14 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
11 Nov 2026Management changeBiocon filed the transcript of its Q2 FY27 earnings call held on November 4, 2026, with the transcript also posted on its website. Management (Chairperson Kiran Mazumdar Shaw and CEO Shreehas Tambe) said the company is moving from investment-led capability building to commercial acceleration and expects H2 FY27 to... NSE copy
04 Nov 2026Management changeBiocon's board approved unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2026, along with a limited review report from the statutory auditors. Board noted the resignation of Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer (Senior Management... NSE copy
04 Nov 2026Management changeBoard of Biocon Limited approved the unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2026, with the statutory auditors' limited review report enclosed. Board noted the resignation of Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer (Senior... NSE copy
07 May 2026Legal or regulatory, Management changeBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of face value Rs. 5) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board... NSE copy
07 May 2026Management changeBoard of Biocon Limited on May 07, 2026 approved audited standalone and consolidated results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of Re. 0.50 per equity share (10% on face value of Rs. 5), with record date July 03, 2026 and payment on or before August 31,... NSE copy
07 May 2026Legal or regulatory, Management changeBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of face value Rs. 5) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board... NSE copy
07 May 2026Legal or regulatory, Management changeBoard approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Board recommended final dividend of 10% (Re. 0.50 per equity share of Rs. 5 face value) for FY2025-26, subject to AGM approval; record date July 03, 2026; payment on or before August 31, 2026. Board... NSE copy
07 May 2026Legal or regulatory, Management changeBoard of Biocon Limited approved audited standalone and consolidated results for the quarter and financial year ended March 31, 2026. Board recommended a final dividend of 10% (Re. 0.50 per equity share of Rs. 5 face value) for FY2026, subject to AGM approval; record date July 03, 2026; payment on or before August... NSE copy
27 Mar 2026Management changeBiocon Limited's board on March 27, 2026 accepted the resignation of Siddharth Mittal as CEO and Managing Director, effective close of business March 31, 2026, to take another role in the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional... NSE copy
27 Mar 2026Management changeBiocon Limited's board, at its meeting on March 27, 2026, accepted the resignation of Siddharth Mittal as CEO and Managing Director effective close of business March 31, 2026, to move to another role in the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited,... NSE copy
27 Mar 2026Management change, ResignationBoard of Biocon Limited, meeting held March 27, 2026, accepted resignation of Siddharth Mittal as CEO and Managing Director effective close of business March 31, 2026, to take another role within the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as... NSE copy
27 Mar 2026Management change, ResignationBiocon Limited's board on March 27, 2026 accepted the resignation of Siddharth Mittal as CEO and Managing Director, effective close of business March 31, 2026, to take another role within the Biocon Group. Board approved appointment of Shreehas Pradeep Tambe, CEO and MD of Biocon Biologics Limited, as Additional... NSE copy
17 Feb 2026Credit ratingBiocon filed the transcript of its Q3 FY26 earnings call held on February 13, 2026. Management said operating revenue was INR 4,173 crores, up 9% year-on-year, with Core EBITDA of INR 1,221 crores (29% margin) and reported net profit of INR 144 crores for the quarter. Management said the planned merger of Biocon... NSE copy
16 Dec 2025Credit ratingBiocon Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit rating. CRISIL Ratings Limited reaffirmed the credit ratings on the Company's bank facilities. Total bank loan facilities rated: Rs. 250 Crore. Long term rating: Crisil AA+/Stable (reaffirmed); short term rating: Crisil... NSE copy
16 Dec 2025Credit ratingBiocon Limited filed intimation of a credit rating from ICRA Limited dated December 16, 2025. ICRA assigned [ICRA]AA+(Stable)/[ICRA]A1+ on Rs. 450.00 crore of Long Term/Short Term unallocated instruments, with the amount unchanged from the previous rated amount. The rating rationale cites Biocon's proposed... NSE copy
10 Dec 2025Credit ratingBiocon Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings, citing India Ratings and Research's press release dated December 09, 2025. India Ratings assigned IND AA+/Stable/IND A1+ to bank loan facilities of INR 5,500 million and assigned IND A1+ to proposed commercial... NSE copy
12 Nov 2025Legal or regulatoryBiocon filed the presentation for its Q2 FY26 earnings call held on November 12, 2025. Q2 FY26 revenue from operations was ₹4,296 crore, up 20% YoY and 9% QoQ; total revenue was ₹4,389 crore; EBITDA was ₹928 crore (21% margin); net profit before exceptional items was ₹92 crore versus a loss of ₹13 crore in Q2 FY25.... NSE copy
11 Nov 2025Legal or regulatoryBiocon filed the outcome of its board meeting held November 11, 2025, approving the unaudited standalone and consolidated Ind-AS financial results for the quarter and half-year ended September 30, 2025. Board approved early full redemption of 50,000 secured rated NCDs of Rs 1,00,000 each, aggregating Rs 500 crores... NSE copy
30 Oct 2025Credit ratingBiocon Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations regarding a credit rating letter dated October 30, 2025 from ICRA Limited. ICRA reaffirmed the rating on Rs. 450 crore of Long-term/Short-term unallocated facilities at [ICRA]AA+ (Stable)/[ICRA]A1+. ICRA's rationale cites the... NSE copy
01 Oct 2025Legal or regulatoryBiocon Limited filed the outcome of its board meeting held on October 01, 2025, under Regulation 30 of the SEBI Listing Regulations. The board approved early full redemption of 1,07,000 unlisted, secured, rated, redeemable NCDs of face value INR 1,00,000 each, aggregating Rs. 1,070 Crores, issued on private... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (33 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in